Edition:
United Kingdom

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

5.10USD
13 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.10
Open
$5.04
Day's High
$5.39
Day's Low
$4.85
Volume
21,310
Avg. Vol
23,422
52-wk High
$6.00
52-wk Low
$2.10

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Reports Q2 Loss Per Share $0.45
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.45.AS OF JUNE 30, 2018, AVENUE'S CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $8.9 MILLION.  Full Article

Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain
Monday, 21 May 2018 

May 21 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - INITIATION OF SECOND PIVOTAL PHASE 3 TRIAL PLANNED FOR Q3 OF 2018.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL.AVENUE THERAPEUTICS INC - IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS.AVENUE THERAPEUTICS - ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019.  Full Article

Avenue Therapeutics Files For Mixed Shelf Offering Of Up To $75 Mln
Friday, 13 Apr 2018 

April 13 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $75 MILLION - SEC FILING.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Avenue Therapeutics reports Q3 loss per share $0.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.30.  Full Article

Avenue therapeutics reports Q2 loss per share $0.70
Friday, 11 Aug 2017 

Aug 11 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics reports second quarter 2017 financial results and recent corporate highlights.Q2 loss per share $0.70.  Full Article

Avenue Therapeutics ic files for IPO of up to $50 mln
Monday, 22 May 2017 

May 22 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc files for IPO of up to $50 million - sec filing.Avenue Therapeutics Inc - expect the public offering price to be between $9.00 and $11.00 per share.Avenue Therapeutics Inc - have applied to list our common stock on the nasdaq capital market under the symbol “atxi.”.Avenue Therapeutics Inc - raymond james, national securities corporation are underwriters to the ipo.Avenue Therapeutics Inc - ipo price is estimated solely for the purpose of computing the amount of the registration fee.  Full Article

Fortress Bio to sell majority stake in brokerage National Holdings

Fortress Biotech Inc said on Monday it will sell its majority stake in the independent wealth management firm National Holdings Corp , bringing an end to an unusual ownership arrangement that had drawn scrutiny from the investing and securities industries.